ID_events | cancer | TypeID | ImmuneCell | P | R | CorrelationPlot |
chr15:43633650-43634492:- | BLCA | EER | Dendritic_cells_activated | 4.8000e-02 | 0.3770 |  |
ENSG00000166762.15,CATSPER2 | BLCA | EAG | T_cells_CD4_naive | 3.8068e-02 | 0.3251 |  |
chr15:43645067-43647038:- | BRCA | EER | T_cells_follicular_helper | 1.6522e-02 | 0.2673 |  |
ENSG00000166762.15,CATSPER2 | BRCA | EAG | Plasma_cells | 2.0271e-04 | 0.3203 |  |
chr15:43633650-43634492:- | CESC | EER | T_cells_follicular_helper | 4.5760e-02 | -0.3614 |  |
ENSG00000166762.15,CATSPER2 | CESC | EAG | T_cells_follicular_helper | 4.8766e-02 | -0.3177 |  |
chr15:43633650-43634492:- | ESCA | EER | Monocytes | 1.3233e-03 | 0.4740 |  |
ENSG00000166762.15,CATSPER2 | ESCA | EAG | T_cells_gamma_delta | 6.7624e-06 | 0.4414 |  |
ENSG00000166762.15,CATSPER2 | KIRC | EAG | NK_cells_resting | 2.8687e-02 | 0.4376 |  |
chr15:43645067-43647038:- | KIRP | EER | T_cells_gamma_delta | 4.3764e-04 | 0.7113 |  |
ENSG00000166762.15,CATSPER2 | KIRP | EAG | T_cells_gamma_delta | 3.4021e-02 | 0.3882 |  |
ENSG00000166762.15,CATSPER2 | LAML | EAG | T_cells_gamma_delta | 8.6152e-03 | 0.4499 |  |
ENSG00000166762.15,CATSPER2 | LUSC | EAG | T_cells_CD4_memory_activated | 8.6033e-03 | -0.4151 |  |
chr15:43633650-43634492:- | OV | EER | Dendritic_cells_activated | 1.7390e-02 | 0.5130 |  |
ENSG00000166762.15,CATSPER2 | PAAD | EAG | B_cells_naive | 4.4312e-02 | 0.4055 |  |
chr15:43645067-43647038:- | PCPG | EER | Neutrophils | 4.1722e-02 | 0.3119 |  |
ID_events | cancer | HallmarkType | Type | P | R | CorrelationPlot |
ENSG00000166762.15,CATSPER2 | BLCA | GSVA_HALLMARK_BILE_ACID_METABOLISM | EAG | 7.0631e-03 | -0.4144 |  |
chr15:43633650-43634492:- | BLCA | GSVA_HALLMARK_PROTEIN_SECRETION | EER | 1.2979e-02 | 0.4635 |  |
ENSG00000166762.15,CATSPER2 | BRCA | GSVA_HALLMARK_PROTEIN_SECRETION | EAG | 1.1058e-02 | -0.2222 |  |
chr15:43645067-43647038:- | BRCA | GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION | EER | 7.4492e-03 | 0.2971 |  |
ENSG00000166762.15,CATSPER2 | CESC | GSVA_HALLMARK_ESTROGEN_RESPONSE_EARLY | EAG | 3.4188e-03 | -0.4574 |  |
chr15:43633650-43634492:- | CESC | GSVA_HALLMARK_GLYCOLYSIS | EER | 9.2335e-03 | -0.4599 |  |
ENSG00000166762.15,CATSPER2 | ESCA | GSVA_HALLMARK_G2M_CHECKPOINT | EAG | 2.3543e-02 | -0.2310 |  |
chr15:43633650-43634492:- | ESCA | GSVA_HALLMARK_KRAS_SIGNALING_DN | EER | 9.2199e-04 | 0.4872 |  |
chr15:43645067-43647038:- | KIRP | GSVA_HALLMARK_TGF_BETA_SIGNALING | EER | 5.0206e-03 | -0.6015 |  |
ENSG00000166762.15,CATSPER2 | KIRP | GSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALING | EAG | 2.4172e-02 | -0.4107 |  |
ENSG00000166762.15,CATSPER2 | LGG | GSVA_HALLMARK_SPERMATOGENESIS | EAG | 6.3046e-04 | -0.5565 |  |
chr15:43645067-43647038:- | OV | GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING | EER | 2.3522e-02 | -0.3620 |  |
chr15:43633650-43634492:- | OV | GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE | EER | 1.7687e-02 | 0.5119 |  |
ENSG00000166762.15,CATSPER2 | PAAD | GSVA_HALLMARK_HYPOXIA | EAG | 3.9571e-02 | -0.4142 |  |
ENSG00000166762.15,CATSPER2 | PCPG | GSVA_HALLMARK_UV_RESPONSE_UP | EAG | 2.4540e-04 | -0.3754 |  |
chr15:43645067-43647038:- | PCPG | GSVA_HALLMARK_PROTEIN_SECRETION | EER | 5.9176e-03 | -0.4130 |  |
ENSG00000166762.15,CATSPER2 | PRAD | GSVA_HALLMARK_HYPOXIA | EAG | 9.8638e-03 | -0.5159 |  |
ID_events | cancer | Drug | Type | P | R | CorrelationPlot |
ENSG00000166762.15,CATSPER2 | BLCA | ABT.263 | EAG | 6.4426e-03 | -0.4187 |  |
chr15:43633650-43634492:- | BLCA | GW.441756 | EER | 6.3241e-03 | 0.5034 |  |
ENSG00000166762.15,CATSPER2 | BRCA | Bleomycin | EAG | 5.2577e-03 | -0.2434 |  |
chr15:43645067-43647038:- | BRCA | Erlotinib | EER | 8.4213e-03 | -0.2927 |  |
ENSG00000166762.15,CATSPER2 | CESC | BIRB.0796 | EAG | 2.8243e-02 | -0.3515 |  |
chr15:43633650-43634492:- | CESC | JNK.Inhibitor.VIII | EER | 7.9802e-03 | -0.4677 |  |
ENSG00000166762.15,CATSPER2 | COAD | Bortezomib | EAG | 4.9896e-03 | -0.5764 |  |
ENSG00000166762.15,CATSPER2 | ESCA | AICAR | EAG | 1.9656e-02 | 0.2378 |  |
chr15:43633650-43634492:- | ESCA | Methotrexate | EER | 7.7764e-04 | 0.4932 |  |
chr15:43645067-43647038:- | ESCA | AICAR | EER | 2.7060e-02 | 0.2293 |  |
ENSG00000166762.15,CATSPER2 | KIRC | DMOG | EAG | 2.0530e-02 | 0.4605 |  |
chr15:43645067-43647038:- | KIRP | GSK.650394 | EER | 2.3555e-03 | 0.6403 |  |
ENSG00000166762.15,CATSPER2 | KIRP | DMOG | EAG | 3.3342e-02 | 0.3896 |  |
ENSG00000166762.15,CATSPER2 | LAML | BMS.509744 | EAG | 5.7775e-03 | 0.4700 |  |
ENSG00000166762.15,CATSPER2 | LGG | AZD.0530 | EAG | 1.1893e-02 | -0.4265 |  |
ENSG00000166762.15,CATSPER2 | OV | Midostaurin | EAG | 4.1098e-03 | 0.3989 |  |
chr15:43645067-43647038:- | OV | GW.441756 | EER | 5.0316e-03 | -0.4403 |  |
chr15:43633650-43634492:- | OV | Axitinib | EER | 1.7539e-03 | 0.6407 |  |
ENSG00000166762.15,CATSPER2 | PAAD | IPA.3 | EAG | 3.3398e-03 | -0.5854 |  |
ENSG00000166762.15,CATSPER2 | PCPG | CCT018159 | EAG | 1.0238e-03 | 0.3387 |  |
ENSG00000166762.15,CATSPER2 | PRAD | GNF.2 | EAG | 4.3565e-02 | 0.4153 |  |
ENSG00000166762.15,CATSPER2 | STAD | Bleomycin | EAG | 1.5345e-02 | -0.1908 |  |
chr15:43645067-43647038:- | STAD | Bleomycin | EER | 2.0924e-02 | -0.1891 |  |